» Articles » PMID: 32518162

Deciphering Site 3 Interactions of Interleukin 12 and Interleukin 23 with Their Cognate Murine and Human Receptors

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2020 Jun 11
PMID 32518162
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Interleukin (IL)-12 and IL-23 belong to the IL-12 type family and are composite cytokines, consisting of the common β subunit p40 and the specific cytokine α subunit p35 and p19, respectively. IL-12 signals via the IL-12Rβ1·IL-12Rβ2 receptor complex, and IL-23 uses also IL-12Rβ1 but engages IL-23R as second receptor. Importantly, binding of IL-12 and IL-23 to IL-12Rβ1 is mediated by p40, and binding to IL-12Rβ2 and IL-23R is mediated by p35 and p19, respectively. Previously, we have identified a W157A substitution at site 3 of murine IL-23p19 that abrogates binding to murine IL-23R. Here, we demonstrate that the analogous Y185R site 3 substitution in murine and Y189R site 3 substitution in human IL-12p35 abolishes binding to IL-12Rβ2 in a cross-species manner. Although Trp is conserved between murine and human IL-23p19 (Trp in the human ortholog), the site 3 W156A substitution in hIL-23p19 did not affect signaling of cells expressing human IL-12Rβ1 and IL-23R, suggesting that the interface of murine IL-23p19 required for binding to IL-23R is different from that in the human ortholog. Hence, we introduced additional hIL-23p19 substitutions within its binding interface to hIL-23R and found that the combined site 3 substitutions of W156A and L160E, which become buried at the complex interface, disrupt binding of hIL-23p19 to hIL-23R. In summary, we have identified substitutions in IL-12p35 and IL-23p19 that disrupt binding to their cognate receptors IL-12Rβ2 and IL-23R in a murine/human cross-species manner.

Citing Articles

Taming interleukin-12: Engineering of bispecific antibody-based IL-12 mimetics with biased agonism capacities.

Lipinski B, Unmuth L, Arras P, Endruszeit R, Becker S, Rodel J Protein Sci. 2025; 34(3):e70072.

PMID: 39981925 PMC: 11843475. DOI: 10.1002/pro.70072.


Anti-PD-1 cis-delivery of low-affinity IL-12 activates intratumoral CD8T cells for systemic antitumor responses.

Zou Z, Shen J, Xue D, Li H, Xu L, Cao W Nat Commun. 2024; 15(1):4701.

PMID: 38830882 PMC: 11148143. DOI: 10.1038/s41467-024-49034-1.


Structures of complete extracellular receptor assemblies mediated by IL-12 and IL-23.

Bloch Y, Felix J, Merceron R, Provost M, Symakani R, De Backer R Nat Struct Mol Biol. 2024; 31(4):591-597.

PMID: 38287195 DOI: 10.1038/s41594-023-01190-6.


Human IL-35 Inhibits the Bioactivity of IL-12 and Its Interaction with IL-12Rβ2.

Mahfooz N, Merling M, Claeys T, Dowling J, Forero A, Robinson R Immunohorizons. 2023; 7(6):431-441.

PMID: 37289499 PMC: 10580122. DOI: 10.4049/immunohorizons.2300039.


Characterisation of IL-23 receptor antagonists and disease relevant mutants using fluorescent probes.

Lay C, Isidro-Llobet A, Kilpatrick L, Craggs P, Hill S Nat Commun. 2023; 14(1):2882.

PMID: 37208328 PMC: 10199020. DOI: 10.1038/s41467-023-38541-2.


References
1.
Kelley L, Mezulis S, Yates C, Wass M, Sternberg M . The Phyre2 web portal for protein modeling, prediction and analysis. Nat Protoc. 2015; 10(6):845-58. PMC: 5298202. DOI: 10.1038/nprot.2015.053. View

2.
Oppmann B, Lesley R, Blom B, Timans J, Xu Y, Hunte B . Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000; 13(5):715-25. DOI: 10.1016/s1074-7613(00)00070-4. View

3.
Bloch Y, Bouchareychas L, Merceron R, Skladanowska K, Van den Bossche L, Detry S . Structural Activation of Pro-inflammatory Human Cytokine IL-23 by Cognate IL-23 Receptor Enables Recruitment of the Shared Receptor IL-12Rβ1. Immunity. 2017; 48(1):45-58.e6. PMC: 5773378. DOI: 10.1016/j.immuni.2017.12.008. View

4.
Ling P, Gately M, Gubler U, Stern A, Lin P, Hollfelder K . Human IL-12 p40 homodimer binds to the IL-12 receptor but does not mediate biologic activity. J Immunol. 1995; 154(1):116-27. View

5.
Fang J, Qian J, Yi S, Harding T, Tu G, VanRoey M . Stable antibody expression at therapeutic levels using the 2A peptide. Nat Biotechnol. 2005; 23(5):584-90. DOI: 10.1038/nbt1087. View